Attach to Form 990 or Form 990-EZ.
Information about Schedule A (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990.
| (i)Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
| Total | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | 16,526,435 | 12,495,973 | 12,253,096 | 12,110,077 | 13,048,070 | 66,433,651 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 16,526,435 | 12,495,973 | 12,253,096 | 12,110,077 | 13,048,070 | 66,433,651 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 20,077,506 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 46,356,145 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 16,526,435 | 12,495,973 | 12,253,096 | 12,110,077 | 13,048,070 | 66,433,651 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 115,592 | 52,754 | 68,767 | 780,822 | 506,380 | 1,524,315 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 68,147 | 108,536 | 233,817 | 510,879 | 761,128 | 1,682,507 |
| 11 | Total support Add lines 7 through 10. | 69,640,473 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2010 | (b) 2011 | (c) 2012 | (d) 2013 | (e) 2014 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e | Discount claimed for blockage or other factors (explain in detail in Part VI): | |||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| 7 | Check here if the current year is the organization's first as a non-functionally-integrated Type III supporting organization (see instructions) | |||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2014 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2014 |
(iii) Distributable Amount for 2014 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2014 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2014 (reasonable cause required--see instructions) |
||||
| 3 Excess distributions carryover, if any, to 2014: | ||||
| a From 2009.......X | ||||
| b From 2010.......X | ||||
| c From 2011.......X | ||||
| d From 2012.......X | ||||
| e From 2013....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2014 distributable amount | ||||
|
i
Carryover from 2009 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2014 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2014 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2014, if any. Subtract lines 3g and 4a from line 2 (if amount greater than zero, see instructions) |
||||
|
6
Remaining underdistributions for 2014. Subtract lines 3h and 4b from line 1 (if amount greater than zero, see instructions) |
||||
|
7 Excess distributions carryover to 2015. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a From 2010.......X | ||||
| b From 2011.......X | ||||
| c From 2012.......X | ||||
| d From 2013....... | ||||
| e From 2014....... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Information about Schedule O (Form 990 or 990-EZ) and its instructions is at| Return Reference | Explanation |
|---|---|
| FORM 990, PART VI, SECTION B, LINE 11 | A COPY OF THE FORM 990 WAS REVIEWED BY THE FINANCE COMMITTEE. AFTERWARDS THE FORM 990 WAS REVEIWED WITH THE BOARD PRIOR TO FILING. |
| FORM 990, PART VI, SECTION B, LINE 12C | THE BOARD MAINTAINS A CONFLICT OF INTEREST POLICY WHICH IS SIGNED ON AN ANNUAL BASIS. IN THE COURSE OF MEETINGS OR ACTIVITIES, EVERYONE WILL DISCLOSE ANY INTERESTS IN A TRANSACTION OR DECISION WHERE HE/SHE (INCLUDING THEIR BUSINESS OR OTHER NON-PROFIT AFFILIATIONS, FAMILY AND/OR SIGNIFICANT OTHER, EMPLOYER OR CLOSE ASSOCIATES) MAY HAVE A CONFLICT. AFTER DISCLOSURE OF ANY POSSIBLE CONFLICT OF INTEREST, THE PERSON WILL BE ASKED TO LEAVE THE ROOM FOR THE DISCUSSION AND WILL NOT BE PERMITTED TO VOTE ON THE QUESTION. |
| FORM 990, PART VI, SECTION B, LINE 15 | HUMAN RESOURCES PREPARES MARKET ANALYSIS OF SALARY SURVEY AND OTHER DATA TO PROVIDE RECOMMENDATIONS TO THE INDEPENDENT COMPENSATION COMMITTEE, WHO REVIEWS THESE DATA ALONG WITH PERFORMANCE EVALUATIONS TO APPROVE ANY SALARY ADJUSTMENTS. |
| FORM 990, PART VI, SECTION C, LINE 18 | THE ORGANIZATION'S FORM 990 IS MADE AVAILABLE TO THE PUBLIC UPON REQUEST AND ON WWW.GUIDESTAR.ORG. |
| FORM 990, PART VI, SECTION C, LINE 19 | THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST STATEMENT, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST. |
| FORM 990, PART XII, LINE 2C: | THIS PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. |
| FORM 990, PART III, LINE 4A: | IN JANUARY 2014, DR. PAUL B. WATKINS, INTERNATIONAL DRUG SAFETY EXPERT AND DIRECTOR OF THE HAMNER-UNIVERSITY OF NORTH CAROLINA INSTITUTE FOR DRUG SAFETY SCIENCES, RECEIVED AN AGILENT THOUGHT LEADER AWARD IN RECOGNITION OF HIS ONGOING WORK DEVELOPING INTEGRATED METHODS TO PREDICT DRUG-INDUCED LIVER INJURY (DILI). THE AWARD CONTINUES AGILENT'S SUPPORT OF THE RESEARCH HAMNER SCIENTISTS ARE CONDUCTING ON DRUG INDUCED LIVER INJURY. DR. WATKINS' STUDIES INVOLVE MOUSE GENETIC MODELS, PATIENTS WHO HAVE EXPERIENCED OR ARE EXPERIENCING DILI, AND PATIENT-SPECIFIC LIVER CULTURE MODELS DERIVED FROM STEM CELLS. ADDITIONALLY IN JANUARY 2014, STEMMING FROM AN ON-GOING COLLABORATION BETWEEN THE JOINT RESEARCH CENTRE'S EUROPEAN UNION REFERENCE LABORATORY FOR ALTERNATIVES TO ANIMAL TESTING (EURL ECVAM) AND THE HAMNER INSTITUTES FOR HEALTH SCIENCES (NC, USA), THE TWO ORGANIZATIONS PUBLISHED A LANDMARK REPORT, "TOXICITY PATHWAYS - FROM CONCEPTS TO APPLICATION IN CHEMICAL SAFETY ASSESSMENT." THE REPORT ADDRESSED KEY QUESTIONS, NAMELY: 1) WHAT CONSTITUTES A TOXICITY PATHWAY?; 2) HOW CAN WE USE TOXICITY PATHWAYS TO DEVELOP IN VITRO ASSAYS AND INTEGRATED TESTING STRATEGIES?; AND, 3) HOW CAN THE RESULTS FROM TOXICITY PATHWAY BASED TESTING SERVE HUMAN HEALTH RISK ASSESSMENTS? IN FEBRUARY 2014, THE HAMNER ANNOUNCED THAT OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC. (OPDC) HAD AGREED TO BECOME THE NEWEST MEMBER OF THE DILI-SIM INITIATIVE. ESTABLISHED IN 2007, OPDC IS A PART OF THE JAPAN-BASED OTSUKA GROUP (OTSUKA) RESPONSIBLE FOR THE RESEARCH AND CLINICAL DEVELOPMENT OF HEALTHCARE PRODUCTS. OTSUKA BECAME THE TWELFTH MEMBER OF THE DILI-SIM CONSORTIUM, JOINING CURRENT MEMBERS AMGEN, ASTRAZENECA, BRISTOL-MYERS SQUIBB, ELI LILLY AND COMPANY, GILEAD, GLAXOSMITHKLINE, JANSSEN RESEARCH & DEVELOPMENT, LLC, MERCK, MITSUBISHI TANABE PHARMA, PFIZER AND SANOFI. IN MARCH 2014, THE HAMNER ANNOUNCED THE LATEST RELEASE OF ITS FLAGSHIP DILI (DRUG-INDUCED LIVERY INJURY) PLATFORM - DILISYM SOFTWARE - VERSION 3A, AS WELL AS VERSION 2A OF ITS MITOSYM SOFTWARE, A MATHEMATICAL MODEL OF MITOCHONDRIAL FUNCTION. DILISYM AND MITOSYM SOFTWARE ARE DEVELOPED AND RELEASED AS PART OF THE DILI-SIM INITIATIVE (WWW.DILISYM.COM), AN EFFORT TO DEVELOP A MATHEMATICAL, MECHANISTIC MODEL OF DRUG-INDUCED LIVER INJURY CHAIRED BY DR. PAUL B. WATKINS. DILISYM V3A AND MITOSYM V2A WERE MADE AVAILABLE TO ALL DILI-SIM INITIATIVE INDUSTRY MEMBERS AS OF MARCH 6, 2014. A MID-YEAR UPDATE, DILISYM V3B, WAS MADE AVAILABLE IN AUGUST 2014. ALSO IN MARCH 2014, THE HAMNER ANNOUNCED THAT ABBVIE INC. HAD AGREED TO BECOME THE NEWEST MEMBER OF THE DILI-SIM INITIATIVE. FOUNDED IN 2013, ABBVIE IS A RESEARCH-BASED GLOBAL BIOPHARMACEUTICAL COMPANY WITH THE FOCUS AND CAPABILITIES TO ADDRESS SOME OF THE WORLD'S GREATEST HEALTH CHALLENGES. ABBVIE BECAME THE THIRTEENTH MEMBER OF THE DILI-SIM CONSORTIUM, JOINING CURRENT MEMBERS AMGEN, ASTRAZENECA, BRISTOL-MYERS SQUIBB, ELI LILLY AND COMPANY, GILEAD, GLAXOSMITHKLINE, JANSSEN RESEARCH & DEVELOPMENT, LLC, MERCK, MITSUBISHI TANABE PHARMA, OTSUKA, PFIZER AND SANOFI. IN APRIL 2014, THE HAMNER ANNOUNCED THAT TAKEDA PHARMACEUTICALS INTERNATIONAL, INC. (TAKEDA) HAD AGREED TO BECOME THE NEWEST MEMBER OF THE DILI-SIM INITIATIVE. HAVING SUSTAINED A LONG CORPORATE HISTORY OF MORE THAN 230 YEARS, TAKEDA CONDUCTS ACTIVITIES ACCORDING TO THE CORPORATE MISSION TO "STRIVE TOWARDS BETTER HEALTH FOR PEOPLE WORLDWIDE THROUGH LEADING INNOVATION IN MEDICINE." TAKEDA BECAME THE FOURTEENTH MEMBER OF THE DILI-SIM CONSORTIUM, JOINING CURRENT MEMBERS ABBVIE, AMGEN, ASTRAZENECA, BRISTOL-MYERS SQUIBB, ELI LILLY AND COMPANY, GILEAD, GLAXOSMITHKLINE, JANSSEN RESEARCH & DEVELOPMENT, LLC, MERCK, MITSUBISHI TANABE PHARMA, OTSUKA, PFIZER AND SANOFI. ADDITIONALLY IN APRIL 2014, THE HAMNER ANNOUNCED THAT ITS SCIENTISTS HAD BEEN RECOGNIZED WITH SIX AWARDS FROM THE SOCIETY OF TOXICOLOGY (SOT), A PROFESSIONAL ORGANIZATION COMMITTED TO CREATING A SAFER AND HEALTHIER WORLD BY ADVANCING THE SCIENCE OF TOXICOLOGY, AT THEIR 53RD ANNUAL MEETING THAT WAS HELD MARCH 23-27 IN PHOENIX, ARIZONA. THE AWARD HONORS FOLLOW AN IMPRESSIVE PRESENCE AT THE MEETING THAT CONSISTED OF OVER 40 PRESENTATIONS BY HAMNER SCIENTISTS. IN TOTAL, EIGHT INSTITUTE SCIENTISTS WERE RECOGNIZED FOR THEIR CONTRIBUTIONS TO VARIOUS TOP ABSTRACTS, POSTERS, AND PAPERS ENCOMPASSING WORK PERFORMED OVER THE LAST YEAR. PARTICULARLY NOTEWORTHY WERE THE ACCOMPLISHMENTS OF DRS. RACHEL CHURCH AND HUALI WU, POSTDOCTORAL FELLOWS WHO EACH RECEIVED NAMED AWARDS AND OTHER HONORS AT THIS YEAR'S MEETING. ADDITIONALLY, DR. QIANG ZHANG, DIRECTOR, CENTER FOR DOSE RESPONSE MODELING AT THE HAMNER, WAS RECOGNIZED FOR HAVING A TOP 10 BEST PAPER OF 2013 IN THE BIOLOGICAL MODELING SPECIALTY SECTION. FOR A COMPLETE LIST OF THE HAMNER'S AWARDS AT SOT, PLEASE VISIT: HTTP://WWW.THEHAMNER.ORG/NEWS-EVENTS/ENTRY/HAMNER-AWARDS-AT-THE-2014- SOCIETY-OF-TOXICOLOGY-ANNUAL-MEETING. IN MAY 2014, IN ALIGNMENT WITH ITS VISION AND COMMITMENT TO TRANSLATIONAL LIFE SCIENCES TRAINING, THE HAMNER INSTRUCTED A THREE-DAY SHORT COURSE FOR OVER 20 PARTICIPANTS FROM MAY 20-22 THAT COVERED THE APPLICATION OF COMPUTATIONAL MODELING PARADIGMS TO HUMAN HEALTH ASSESSMENTS. JOINTLY ORGANIZED BY THE HAMNER'S INSTITUTE FOR CHEMICAL SAFETY SCIENCES AND THE HOST CENTER FOR INTEGRATIVE TOXICOLOGY AT MICHIGAN STATE UNIVERSITY, THE COURSE FEATURED COMPREHENSIVE LECTURES AND EXTENSIVE HANDS-ON COMPUTER MODELING PRACTICE, AND WAS DESIGNED TO SERVE A VARIETY OF SCIENTIFIC COMMUNITIES, INCLUDING INDUSTRIAL, PHARMACEUTICAL AND REGULATORY SCIENTISTS, TOXICOLOGISTS AND RESEARCH SCIENTISTS, AND INDIVIDUALS INTERESTED IN PROMOTING THE USE OF ALTERNATIVES TO LIVE ANIMAL TESTING. IN SEPTEMBER 2014, IN ALIGNMENT WITH ITS VISION AND COMMITMENT TO TRANSLATIONAL LIFE SCIENCES TRAINING, THE HAMNER INSTRUCTED A ONE WEEK COURSE FOR OVER 25 PARTICIPANTS FROM MONDAY, SEPT. 22 THROUGH FRIDAY, SEPT. 26 THAT COVERED THE APPLICATION OF COMPUTATIONAL MODELING PARADIGMS TO HUMAN HEALTH ASSESSMENTS. THE COURSE FEATURED COMPREHENSIVE LECTURES AND EXTENSIVE HANDS-ON COMPUTER MODELING PRACTICE, AND WAS DESIGNED TO SERVE A VARIETY OF SCIENTIFIC COMMUNITIES, INCLUDING INDUSTRIAL, PHARMACEUTICAL AND REGULATORY SCIENTISTS, TOXICOLOGISTS AND RESEARCH SCIENTISTS, AND INDIVIDUALS INTERESTED IN PROMOTING THE USE OF ALTERNATIVES TO LIVE ANIMAL TESTING. ALSO IN SEPTEMBER 2014, RESEARCHERS AT THE UNC ESHELMAN SCHOOL OF PHARMACY, USING THE HAMNER'S DILISYM SOFTWARE, PUBLISHED A LANDMARK PAPER IN THE JOURNAL CLINICAL PHARMACOLOGY AND THERAPEUTICS THAT THEY BELIEVE SOLVES THE MYSTERY OF WHY A DIABETES DRUG INTRODUCED IN 1997 CAUSED LIVER FAILURE AND DEATH IN SIXTY-THREE PATIENTS. THEIR DISCOVERY MAKES IT LIKELY THAT SIMILAR DRUG-RELATED DEATHS CAN BE PREVENTED IN THE FUTURE. HAMNER INVESTIGATORS WERE CO-AUTHORS ON THE PUBLICATION. IN OCTOBER 2014, ENVIRON, AN INTERNATIONAL ENVIRONMENTAL, HEALTH, SAFETY AND SUSTAINABILITY CONSULTANCY, ANNOUNCED THAT DR. HARVEY CLEWELL III, DIRECTOR OF THE HAMNER'S CENTER FOR HUMAN HEALTH ASSESSMENT, HAD REJOINED THE FIRM AS A PRINCIPAL CONSULTANT AND WILL WORK CLOSELY WITH SENIOR PROFESSIONALS IN ENVIRON'S HEALTH SCIENCES PRACTICE. DR. CLEWELL WILL ALSO CONTINUE TO SERVE IN HIS CURRENT POSITION AT THE HAMNER INSTITUTES FOR HEALTH SCIENCES (THE HAMNER) IN RESEARCH TRIANGLE PARK, NORTH CAROLINA. THIS NEW FORMAL COLLABORATIVE RELATIONSHIP BETWEEN ENVIRON AND THE HAMNER CONTINUES A SUCCESSFUL HISTORY OF PARTNERING ON VARIOUS RESEARCH AND ASSESSMENT PROJECTS. IN FACT, DR. CLEWELL SERVED AS A PRINCIPAL AT ENVIRON FOR 12 YEARS BEFORE JOINING THE HAMNER IN 2005. THIS RELATIONSHIP ALSO BRINGS INCREASED SCIENTIFIC EXPERTISE TO ENVIRON THROUGH THE HAMNER'S PARTNERSHIPS WITH ACADEMIA, INDUSTRY AND GOVERNMENT, AS WELL AS THEIR TRANSLATION OF INNOVATIVE LIFE SCIENCES AND BIOMEDICAL RESEARCH THROUGH THE DEVELOPMENT AND INTEGRATION OF CUTTING-EDGE SAFETY SCIENCE PREDICTIVE TECHNOLOGIES. ALSO IN OCTOBER 2014, HAMNER ICSS SCIENTISTS CO-HOSTED THE FIRST WORKSHOP AND LABORATORY-BASED TRAINING COURSE FOR SYSTEMS TOXICOLOGY IN CHINA. THE INTERNATIONAL WORKSHOP, ENTITLED "SYSTEMS TOXICOLOGY: DEVELOPING MECHANISTIC UNDERSTANDING OF TOXICITY PATHWAYS AND ESTABLISHING PREDICTIVE TOXICOLOGY FOR USE IN RISK ASSESSMENTS," BROUGHT TOGETHER GLOBAL EXPERTS FROM INDUSTRY, ACADEMIA, AND GOVERNMENT TO DISCUSS A WIDE RANGE OF TOPICS AND SHARE THEIR OWN EXPERIENCES DEVELOPING AND IMPLEMENTING SYSTEMS TOXICOLOGY APPROACHES. IN ADDITION TO THE HAMNER, LEADING SCIENTISTS FROM AGILENT TECHNOLOGIES, CELLULAR DYNAMICS INTERNATIONAL, ACEA BIOSCIENCES, STRAND LIFE SCIENCES, STEMINA BIOMARKER DISCOVERY, AND THE U.S. NIH NCATS, GATHERED AT THE AGILENT CENTER OF EXCELLENCE IN BEIJING TO PROVIDE PARTICIPANTS THE OPPORTUNITY TO LEARN THE BASIS AND APPLICATION OF VARIOUS SYSTEMS TOXICOLOGY DISCIPLINES. |
| FORM 990, PART III, LINE 4A: | IN NOVEMBER 2014, HAMNER-UNC INSTITUTE FOR DRUG SAFETY SCIENCES DIRECTOR DR. PAUL B. WATKINS WAS AWARDED THE 2015 RAWLS-PALMER PROGRESS IN MEDICINE AWARD FROM THE AMERICAN INSTITUTE OF CLINICAL PHARMACOLOGY AND THERAPEUTICS FOR MULTIPLE CONTRIBUTIONS TO THE FIELD OF CLINICAL PHARMACOLOGY. ESTABLISHED IN 1978, THE RAWLS-PALMER AWARD IS GIVEN TO THOSE WHO CONTRIBUTE MEANINGFUL RESEARCH THAT IMPROVES PATIENT CARE. WATKINS HAS BEEN INVITED TO GIVE MORE THAN 180 TALKS WORLDWIDE REGARDING HIS RESEARCH ON ENZYMES THAT METABOLIZE MEDICATION, GRAPEFRUIT-DRUG INTERACTIONS, AND DRUG-INDUCED LIVER INJURY. WITH MORE THAN 170 ORIGINAL MANUSCRIPTS AND THIRTY BOOK CHAPTERS PUBLISHED, WATKINS' RESEARCH HAS BEEN CITED MORE THAN 14,000 TIMES. WATKINS IS ONE OF SEVEN PEOPLE TO WIN A 2015 ASCPT AWARD AND WILL RECEIVE OFFICIAL RECOGNITION DURING THE 2015 ANNUAL ASCPT MEETING IN MARCH. THE HAMNER INSTITUTES FOR HEALTH SCIENCES AND THE EUROPEAN INNOVATIVE MEDICINES INITIATIVE (IMI) CO-SPONSORED A 2012 WORKSHOP IN BOSTON ON BEST PRACTICES IN CLINICAL LIVER SAFETY ASSESSMENT THAT INCLUDED ACADEMIC AND INDUSTRY LEADERS AND ALSO REGULATORS FROM FDA, HEALTH CANADA, EUROPEAN MEDICINES AGENCY, AND REGULATORS FROM JAPAN AND CHINA. THE OUTCOME OF THIS WORKSHOP WAS SIX WHITE PAPERS TO BE PUBLISHED TOGETHER IN DECEMBER 2014 IN THE JOURNAL "DRUG SAFETY". TO ACCESS THIS REPORT, PLEASE CLICK THE LINK BELOW: HTTP://LINK.SPRINGER.COM/JOURNAL/40264/37/1/SUPPL/PAGE/1. |
| Software ID: | |
| Software Version: |